Sanofi to invest $27m in Ventyx Biosciences.

Sanofi, a French multinational pharmaceutical and healthcare company, agreed to invest $27m in Ventyx Biosciences, a clinical-stage biopharmaceutical company. The proceeds from the investment are expected to further strengthen the Company’s cash position, and current cash, cash equivalents and marketable securities, inclusive of the proceeds from the investment, are expected to be sufficient to fund planned operations into at least the second half of 2026.